keyword
MENU ▼
Read by QxMD icon Read
search

Desvenlafaxine

keyword
https://www.readbyqxmd.com/read/28725139/hybrid-polymeric-matrices-for-oral-modified-release-of-desvenlafaxine-succinate-tablets
#1
Wael Samy, Ayman Elnoby, Hanan M El-Gowelli, Nazik Elgindy
Purpose: Desvenlafaxine succinate (DSV) is a water soluble anti-depressant drug, which is rapidly absorbed after oral administration exaggerating its side effects. The current work aimed to prepare controllable release DSV matrix to reduce DSV side effects related to its initial burst. Methods: Fifteen DSV matrix formulations were prepared using different polymers, polymer/drug ratios and matrix excipients and characterized using Differential Scanning Calorimetry (DSC), infrared (IR) spectroscopy, water uptake and in vitro DSV release...
July 2017: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/28718346/effect-of-desvenlafaxine-50-mg-and-100-mg-on-energy-and-lassitude-in-patients-with-major-depressive-disorder-a-pooled-analysis
#2
Raymond W Lam, Dalia B Wajsbrot, Ellen Meier, Elizabeth Pappadopulos, Joan A Mackell, Matthieu Boucher
Nine randomized, double-blind, placebo-controlled studies of major depressive disorder were pooled to evaluate the effects of desvenlafaxine 50- and 100-mg/d on energy and lassitude in adults with major depressive disorder ( n=4279). Changes from baseline to endpoint in 17-item Hamilton Rating Scale for Depression (HAM-D17) Work and Activities, Retardation, and Somatic Symptoms General items, HAM-D17 psychomotor retardation factor, and Montgomery-Åsberg Depression Rating Scale Lassitude item were analyzed with a mixed model for repeated measures analysis of variance...
July 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28649145/do-ssris-and-snris-reduce-the-frequency-and-or-severity-of-hot-flashes-in-menopausal-women
#3
Chris Stubbs, Lisa Mattingly, Steven A Crawford, Elizabeth A Wickersham, Jessica L Brockhaus, Laine H McCarthy
CLINICAL QUESTION: In menopausal women who experience regular hot flashes, does treatment with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) reduce the frequency and/or severity of hot flashes? ANSWER: Yes. Review of the literature suggests that treatment with SSRIs or SNRIs reduces the frequency and severity of hot flashes in menopausal and post-menopausal women. Studies demonstrated that paroxetine (Paxil), citalopram (Celexa) and escitolapram (Lexapro) were the most effective SSRIs, and venlafaxine (Effexor) was the most effective first line SNRI, with desvenlafaxine as a second option...
May 2017: Journal of the Oklahoma State Medical Association
https://www.readbyqxmd.com/read/28605847/impact-of-on-site-small-and-large-scale-wastewater-treatment-facilities-on-levels-and-fate-of-pharmaceuticals-personal-care-products-artificial-sweeteners-pesticides-and-perfluoroalkyl-substances-in-recipient-waters
#4
Pablo Gago-Ferrero, Meritxell Gros, Lutz Ahrens, Karin Wiberg
One of the main risks associated with effluents from both wastewater treatment plants (WWTPs) and on-site sewage treatment facilities (OSSFs) is the release of micropollutants (MPs) in receiving water bodies. However, the impact of MPs present in the effluents of OSSFs in the aquatic environment has not been studied so far. The current study evaluates the impact of the effluents of OSSFs and small-to-large scale WWTPs on natural waters. The discharge of 74 MPs was assessed including pharmaceuticals, personal care products, pesticides, artificial sweeteners and perfluoroalkyl substances (PFASs)...
June 6, 2017: Science of the Total Environment
https://www.readbyqxmd.com/read/28465217/antidepressants-induce-autophagy-dependent-nlrp3-inflammasome-inhibition-in-major-depressive-disorder
#5
Elísabet Alcocer-Gómez, Nieves Casas-Barquero, Matthew R Williams, Samuel L Romero-Guillena, Diego Cañadas-Lozano, Pedro Bullón, José Antonio Sánchez-Alcazar, José M Navarro-Pando, Mario D Cordero
Major Depressive Disorder (MDD, ICD-10: F-33) is a prevalent illness in which the pathogenic mechanism remains elusive. Recently an important role has been attributed to neuro-inflammation, and specifically the NLRP3-inflammasome complex, in the pathogenesis of MDD. This suggests a key role for immunomodulation as a key pathway in the treatment of this disorder. This study evaluates the involvement of nine common antidepressants in the NLRP3-inflammasome complex (fluoxetine, paroxetine, mianserin, mirtazapine, venlafaxine, desvenlafaxine, amitriptyline, imipramine and agomelatine), both in in vitro THP-1 cells stimulated by ATP, and in a stress-induced depressive animal or MDD patients...
May 2, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28334528/why-prodrugs-and-propesticides-succeed
#6
REVIEW
John E Casida
What are the advantages of bioactivation in optimizing drugs and pesticides? Why are there so many prodrugs and propesticides? These questions are examined here by considering compounds selected on the basis of economic value or market success in 2015. The 100 major drugs and 90 major pesticides are divided into ones acting directly and those definitely or possibly requiring bioactivation. Established or candidate prodrugs accounted for 19% of the total drug sales, with corresponding values of 20, 37, and 17% for proinsecticides, proherbicides, and profungicides...
May 15, 2017: Chemical Research in Toxicology
https://www.readbyqxmd.com/read/28250562/comparison-of-effect-of-antidepressants-on-psychomotor-functions
#7
Pranjali P Mendhe, Samidh P Shah, Mira K Desai, Minakshi N Parikh
OBJECTIVE: The comparison of the effect of antidepressants on psychomotor functions in patients with endogenous depression. MATERIALS AND METHODS: This prospective interventional study was carried out at a tertiary care teaching hospital on 95 literate patients with newly diagnosed endogenous depression matching inclusion and exclusion criteria. Patients were prescribed either desvenlafaxine (50 mg) or fluoxetine (40 mg) or sertraline (50 mg). Psychomotor functions were assessed by digit letter substitution, six letter cancellation, choice reaction time, hand steadiness and flicker fusion test at the baseline 1(st) month and 3(rd) month...
January 2017: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/28229443/-desvenlafaxine-and-neuropathic-pain-additional-clinical-benefits-of-a-second-generation-serotonin-noradrenaline-reuptake-inhibitor
#8
REVIEW
A Alcantara-Montero
INTRODUCTION: Desvenlafaxine is the third antidepressant within the group of serotonin-norepinephrine reuptake inhibitors. The latest clinical practice guidelines consulted agree that tricyclic antidepressants, dual (venlafaxine/duloxetine) and gabapentin/pregabalin antiepileptics, are the first-line drugs in the treatment of neuropathic pain, being tramadol, lidocaine 5% patches and capsaicin 8% patches of second-line drugs, while strong opioids constitute a third line treatment. The interaction between the binomial pain and depression is very frequent, being the psychological complication more frequent in patients with chronic pain...
March 1, 2017: Revista de Neurologia
https://www.readbyqxmd.com/read/28159109/multi-residue-determination-of-micropollutants-in-phragmites-australis-from-constructed-wetlands-using-microwave-assisted-extraction-and-ultra-high-performance-liquid-chromatography-tandem-mass-spectrometry
#9
Bruce Petrie, Benjamin D Smith, Jane Youdan, Ruth Barden, Barbara Kasprzyk-Hordern
In constructed wetlands micropollutants can be removed from water by phytoremediation. However, micropollutant uptake and metabolism by plants here is poorly understood due to the lack of good analytical approaches. Reported herein is the first methodology developed and validated for the multi-residue determination of 81 micropollutants (pharmaceuticals, personal care products and illicit drugs) in the emergent macrophyte Phragmites australis. The method involved extraction by microwave accelerated extraction (MAE), clean-up using off-line solid phase extraction and analysis by ultra-high-performance liquid chromatography tandem mass spectrometry...
March 22, 2017: Analytica Chimica Acta
https://www.readbyqxmd.com/read/28146000/efficacy-of-desvenlafaxine-compared-with-placebo-in-major-depressive-disorder-patients-by-age-group-and-severity-of-depression-at-baseline
#10
Daniel Mosca, Min Zhang, Rita Prieto, Matthieu Boucher
PURPOSE: This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50 and 100 mg versus placebo across age groups and severity of depression at baseline in patients with major depressive disorder. METHODS: Data from placebo and desvenlafaxine 50-mg and 100-mg dose arms were pooled from 9 short-term, placebo-controlled, major depressive disorder studies (N = 4279). Effects of age (18-40 years, >40 to <55 years, 55-<65 years, and ≥65 years) and baseline depression severity (mild, 17-item Hamilton Rating Scale for Depression total score [HAM-D17] ≤18; moderate, HAM-D17 >18 to <25; severe, HAM-D17 ≥25) on desvenlafaxine efficacy were assessed using analysis of covariance for continuous end points and logistic regression for categorical end points...
April 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28079059/co-variation-of-peripheral-levels-of-mir-1202-and-brain-activity-and-connectivity-during-antidepressant-treatment
#11
Juan Pablo Lopez, Fabricio Pereira, Stéphane Richard-Devantoy, Marcelo Berlim, Eduardo Chachamovich, Laura M Fiori, Paola Niola, Gustavo Turecki, Fabrice Jollant
MicroRNAs are short non-coding molecules that play a major role in regulating gene expression. Peripheral levels of miR-1202 have been shown to predict and mediate antidepressant response. However, it is not clear to what extent these peripheral measures reflect central neural changes in vivo. We approached this problem with the combined use of peripheral miR-1202 measures and neuroimaging. At baseline and after 8 weeks of Desvenlafaxine (50-100 mg die), twenty patients were scanned with 3T Magnetic Resonance Imaging, first at rest then during the Go/NoGo task, a classical test of response inhibition...
January 12, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28074989/-antidepressants-agents-in-breast-cancer-patients-using-tamoxifen-review-of-basic-and-clinical-evidence
#12
REVIEW
María Elisa Irarrázaval O, Leonardo Gaete G
Tamoxifen (Tmf), is a standard of care for women with estrogen receptor positive (ER+) breast cancer. Endoxifen is a Tmf metabolite generated by cytochrome P450 2D6 (CYP2D6). Antidepressive agents (AD) are often prescribed to women with breast cancer not only for depression, but also for anxiety and hot flashes. Some AD are substrates or inhibitors of the Tmf metabolic pathway. Therefore there may be interactions when Tmf and AD are prescribed simultaneously. Oncologic protection afforded by Tmf may become less effective or null when AD are indicated, especially in poor metabolizing patients...
October 2016: Revista Médica de Chile
https://www.readbyqxmd.com/read/28064115/do-social-functioning-and-symptoms-improve-with-continuation-antidepressant-treatment-of-persistent-depressive-disorder-an-observational-study
#13
David J Hellerstein, Kallio Hunnicutt-Ferguson, Jonathan W Stewart, Patrick J McGrath, Samantha Keller, Bradley S Peterson, Ying Chen
OBJECTIVE: To determine efficacy of continued treatment with the serotonin norepinephrine reuptake inhibitor duloxetine on symptom reduction and functional improvement in outpatients with dysthymia. METHOD: Fifty outpatients with DSM-IV-TR diagnosed dysthymia who had participated in a 10 week double-blind, placebo-controlled study of duloxetine received open treatment for three months. Nineteen duloxetine responders continued duloxetine, 24 patients initially treated with placebo started open duloxetine treatment, and 7 duloxetine non-responders were treated with desvenlafaxine or bupropion, selected by clinician choice...
December 20, 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/27959497/inhibition-of-the-serotonin-transporter-is-altered-by-metabolites-of-selective-serotonin-and-norepinephrine-reuptake-inhibitors-and-represents-a-caution-to-acute-or-chronic-treatment-paradigms
#14
Danielle Krout, Meghan Rodriquez, Stephen A Brose, Mikhail Y Golovko, L Keith Henry, Brent J Thompson
Previous studies of transgenic mice carrying a single isoleucine to methionine substitution (I172M) in the serotonin transporter (SERT) demonstrated a loss of sensitivity to multiple antidepressants (ADs) at SERT. However, the ability of AD metabolites to antagonize SERT was not assessed. Here, we evaluated the selectivity and potency of these metabolites for inhibition of SERT in mouse brain-derived synaptosomes and blood platelets from wild-type (I172 mSERT) and the antidepressant-insensitive mouse M172 mSERT...
May 17, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/27822048/analysis-of-treatment-patterns-and-persistence-on-branded-and-generic-medications-in-major-depressive-disorder-using-retrospective-claims-data
#15
Caitlyn T Solem, Ahmed Shelbaya, Yin Wan, Chinmay G Deshpande, Jose Alvir, Elizabeth Pappadopulos
BACKGROUND: In major depressive disorder (MDD), treatment persistence is critical to optimize symptom remission, functional recovery, and health care costs. Desvenlafaxine tends to have fewer drug interactions and better tolerability than other MDD drugs; however, its use has not been assessed in the real world. OBJECTIVE: The aim of the present study is to compare medication persistence and concomitant MDD drug use with branded desvenlafaxine (Pristiq(®)) compared with antidepressant drug groups classified as 1) branded selective serotonin reuptake inhibitors (SSRIs; ie, escitalopram [Lexapro™]) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs; ie, venlafaxine [Effexor(®)], duloxetine [Cymbalta(®)]) and 2) generic SSRIs/SNRIs (ie, escitalopram, citalopram, venlafaxine, fluvoxamine, fluoxetine, sertraline, paroxetine, and duloxetine)...
2016: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/27788313/efficacy-of-cognitive-behavioral-therapy-for-insomnia-combined-with-antidepressant-pharmacotherapy-in-patients-with-comorbid-depression-and-insomnia-a-randomized-controlled-trial
#16
RANDOMIZED CONTROLLED TRIAL
Rachel Manber, Daniel J Buysse, Jack Edinger, Andrew Krystal, James F Luther, Stephen R Wisniewski, Mickey Trockel, Helena C Kraemer, Michael E Thase
OBJECTIVES: The Treatment of Insomnia and Depression (TRIAD) study evaluated the efficacy of combining depression pharmacotherapy (using MED, an ecologically valid and generalizable antidepressant medication algorithm) with cognitive-behavioral therapy for insomnia (CBT-I) among individuals with comorbid insomnia and major depressive disorder (MDD) to determine if change in insomnia severity mediates antidepressant outcome. METHODS: This 16-week, 3-site, randomized controlled trial (RCT) randomly assigned 150 participants (recruited between March 2009 and August 2013), who met DSM-IV-TR criteria for insomnia and MDD and were not receiving treatment for either, to receive depression pharmacotherapy plus 7 sessions of either CBT-I or a credible control therapy for insomnia (CTRL)...
October 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27784414/are-patients-with-childhood-onset-of-insomnia-and-depression-more-difficult-to-treat-than-are-those-with-adult-onsets-of-these-disorders-a-report-from-the-triad-study
#17
Jack D Edinger, Rachel Manber, Daniel J Buysse, Andrew D Krystal, Michael E Thase, Phillip Gehrman, Christopher P Fairholme, James Luther, Stephen Wisniewski
STUDY OBJECTIVES: To determine if patients with childhood onsets (CO) of both major depression and insomnia disorder show blunted depression and insomnia treatment responses to concurrent interventions for both disorders compared to those with adult onsets (AO) of both conditions. METHODS: This study was a secondary analysis of data obtained from a multisite randomized clinical trial designed to test the efficacy of combining a psychological/behavior insomnia therapy with antidepressant medication to enhance depression treatment outcomes in patients with comorbid major depression and insomnia...
February 15, 2017: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://www.readbyqxmd.com/read/27779571/concordance-between-actual-and-pharmacogenetic-predicted-desvenlafaxine-dose-needed-to-achieve-remission-in-major-depressive-disorder-a-10-week-open-label-study
#18
Chad A Bousman, Daniel J Müller, Chee H Ng, Keith Byron, Michael Berk, Ajeet B Singh
BACKGROUND: Pharmacogenetic-based dosing support tools have been developed to personalize antidepressant-prescribing practice. However, the clinical validity of these tools has not been adequately tested, particularly for specific antidepressants. OBJECTIVE: To examine the concordance between the actual dose and a polygene pharmacogenetic predicted dose of desvenlafaxine needed to achieve symptom remission. MATERIALS AND METHODS: A 10-week, open-label, prospective trial of desvenlafaxine among Caucasian adults with major depressive disorder (n=119) was conducted...
January 2017: Pharmacogenetics and Genomics
https://www.readbyqxmd.com/read/27696548/spectroscopic-exploration-and-thermodynamic-characterization-of-desvenlafaxine-interacting-with-fluorescent-bovine-serum-albumin
#19
Manjanath Patgar, Amar Durgannavar, Sharanappa Nandibewoor, Shivamurti Chimatadar
The mechanism of the interaction between bovine serum albumin (BSA) and desvenlafaxine was studied using fluorescence, ultraviolet absorption, 3-dimensional fluorescence spectroscopy, circular dichroism, synchronous fluorescence spectroscopy, cyclic voltametry, differential scanning calorimetry, and attenuated total reflection-Fourier transform infrared spectroscopic techniques under physiological condition at pH 7.4. Stern-Volmer calculations authenticate the fluorescence of BSA that was quenched by desvenlafaxine in a collision quenching mode...
October 3, 2016: Journal of Molecular Recognition: JMR
https://www.readbyqxmd.com/read/27622824/desvenlafaxine-overdose-and-the-occurrence-of-serotonin-toxicity-seizures-and-cardiovascular-effects
#20
J M Cooper, J A Brown, R Cairns, G K Isbister
CONTEXT: Desvenlafaxine is used to treat major depression. Desvenlafaxine is also the active metabolite of venlafaxine. Venlafaxine overdose can cause serotonin toxicity, seizures and cardiovascular effects, but there is limited information on desvenlafaxine overdose. OBJECTIVE: We aimed at investigating the clinical effects and complications from desvenlafaxine overdose. MATERIALS AND METHODS: This was a retrospective observational study of desvenlafaxine overdoses over a six-year period...
January 2017: Clinical Toxicology
keyword
keyword
48023
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"